Business Description

Description
Gamida Cell Ltd is a clinical-stage biopharmaceutical company that is pioneering a diverse immunotherapy pipeline of potentially curative cell therapy candidates for patients with solid tumors and blood cancers and other serious blood diseases. The company applies a proprietary expansion platform leveraging the properties of nicotinamide, or NAM, to allogeneic cell sources including umbilical cord blood-derived cells and natural killer, or NK, cells to create cell therapy candidates with the potential to redefine standards of care. Its primary product candidate is Omidubicel, an advanced cell therapy candidate for allogeneic hematopoietic stem cell transplant and GDA-201 is the company's lead investigational NK cell-based cancer immunotherapy product candidate.

Financial Strength

Name Current Vs Industry Vs History
Cash-To-Debt 0.71
Debt-to-Equity 223.08
Debt-to-EBITDA -1.12
Piotroski F-Score 3/9
0
1
2
3
4
5
6
7
8
9
Altman Z-Score -6.76
Distress
Grey
Safe
WACC vs ROIC
WACC
ROIC

Growth Rank

Name Current Vs Industry Vs History
3-Year EBITDA Growth Rate -3.2
3-Year EPS without NRI Growth Rate 17.7
3-Year FCF Growth Rate 4.5

Momentum Rank

Name Current Vs Industry Vs History
5-Day RSI 9.62
9-Day RSI 16.8
14-Day RSI 22.5
6-1 Month Momentum % -63.24
12-1 Month Momentum % -52.03

Liquidity Ratio

Name Current Vs Industry Vs History
Current Ratio 3.32
Quick Ratio 3.2
Cash Ratio 2.93
Days Inventory 1374.29
Days Sales Outstanding 366.63
Days Payable 1959.34

Dividend & Buy Back

Name Current Vs Industry Vs History
3-Year Average Share Buyback Ratio -30.4
Shareholder Yield % -197.96

Profitability Rank

Name Current Vs Industry Vs History
Gross Margin % 6.98
Operating Margin % -11438.78
Net Margin % -11434.03
FCF Margin % -12385.88
ROA % -66.98
ROIC % -137.49
ROC (Joel Greenblatt) % -159.41
ROCE % -83.1

GF Value Rank

Name Current Vs Industry Vs History
PS Ratio 10.85
EV-to-EBIT -0.42
EV-to-Forward-EBIT -1.08
EV-to-EBITDA -0.43
EV-to-Revenue 48.08
EV-to-Forward-Revenue 11.24
EV-to-FCF -0.39
Earnings Yield (Greenblatt) % -238.1
FCF Yield % -1740.96

Financials (Next Earnings Date:2024-05-15 Est.)

GMDA's 30-Y Financials
Income Statement Breakdown
No Enough Data
Balance Sheet Breakdown
No Enough Data
Cashflow Statement Breakdown
No Enough Data

Historical Operating Revenue by Business Segment

Historical Operating Revenue by Geographic Region

5-Step DuPont Analysis as of
No Enough Data

Guru Trades

See Details
To

Insider Trades

See Details
To

Gurus Latest Trades with NAS:GMDA

No Available Data

Peter Lynch Chart

Y-axis scale:
Interactive Chart
To

Performance

Dividend
Log
Bar
To

Annualized Return %  

Symbol
1 Week
1 Month
3 Months
6 Months
YTD
1 Year
3 Years
5 Years
10 Years

Total Annual Return %  

Symbol
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015

Gamida Cell Ltd Executives

Details

GF Value

Valuation Chart

Year:

Analyst Estimate

Key Statistics

Name Value
Revenue (TTM) (Mil $) 0.673
EPS (TTM) ($) -0.88
Beta 0.54
Volatility % 143.49
14-Day RSI 22.5
14-Day ATR ($) 0.05677
20-Day SMA ($) 0.33982
12-1 Month Momentum % -52.03
52-Week Range ($) 0.0346 - 2.51
Shares Outstanding (Mil) 132.64

Piotroski F-Score Details

Year:
Component Result
Piotroski F-Score 3
Positive ROA
Positive CFROA
Higher ROA yoy
CFROA > ROA
Lower Leverage yoy
Higher Current Ratio yoy
Less Shares Outstanding yoy
Higher Gross Margin yoy
Higher Asset Turnover yoy

Gamida Cell Ltd Filings

Filing Date Document Date Form
No Filing Data

Gamida Cell Ltd Stock Events

Financials Calendars
Event Date Price($)
No Event Data

Gamida Cell Ltd Frequently Asked Questions

What is Gamida Cell Ltd(GMDA)'s stock price today?
The current price of GMDA is $0.04. The 52 week high of GMDA is $2.51 and 52 week low is $0.03.
When is next earnings date of Gamida Cell Ltd(GMDA)?
The next earnings date of Gamida Cell Ltd(GMDA) is 2024-05-15 Est..
Does Gamida Cell Ltd(GMDA) pay dividends? If so, how much?
Gamida Cell Ltd(GMDA) does not pay dividend.

Press Release

Subject Date
No Press Release

Headlines

See More
  • 1
No news.
  • 1